AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10050221
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 1.0 mg/h
Trial: 2041927
Drug: Erythromycin tablets
RxNorm normalized name: Erythromycin Tablets
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin tablets (Abboticin 500 mg tablets)
Trial: 2041927
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid cream (Fucidin cream)
Trial: 26260018
Drug: CO2 fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 fractional laser treatment (3 sessions every 4-6 weeks)
Trial: 21747289
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration (OR) with D2O labeled fluid
Trial: 21747289
Drug: Oral combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combined with intravenous rehydration (IVO) with D2O labeled fluid
Trial: 9758292
Drug: Trovafloxacin 100
RxNorm normalized name: trovafloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin 100 or 200 mg
Trial: 9758292
Drug: Comparator (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid)
Trial: 7798463
Drug: Simulated exclusion
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated exclusion criteria (borderline personality disorder, drug/alcohol dependence, and others)
Trial: 26888806
Drug: rhBNP administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhBNP administration (1.5 µg/kg bolus intravenous injection followed by 0.0075-0.03 µg·kg(‐1)·min(‐1) for up to 120 hours)
Trial: 26888806
Drug: NIT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIT treatment (10-100 µg/min intravenous infusion for 120 hours)
Trial: 23963331
Drug: G‐CSF (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (135 µg/kg body weight intravenous over 72 hours)
Trial: 18326136
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol and remifentanil (Group R)
Trial: 8869763
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of morphine
Trial: 8869763
Drug: Pupillometric study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pupillometric study with morphine
Trial: 1290604
Drug: Dentin bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentin bonding agents (8 different types)
Trial: 6427027
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate alone (50 mg/day, cycle days 5 to 9)
Trial: 25283499
Drug: Telbivudine preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine preemptive therapy
Trial: 21139575
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral therapy
Trial: 22404442
Drug: LA-CT (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-CT (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + tetracycline 500 mg q.i.d. for 2nd week)
Trial: 22404442
Drug: LA-CM (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-CM (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + metronidazole 500 mg t.i.d. for 2nd week)
Trial: 18080055
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet)
Trial: 18080055
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet)
Trial: 18080055
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet) in moderate disease subgroup
Trial: 18080055
Drug: Delayed-release oral
RxNorm normalized name: Prevacid 1 MG/ML Delayed-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) in moderate disease subgroup
Trial: 19888035
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (2 mg)
Trial: 11341495
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 microg)
Trial: 412995
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucose, fructose and xylitol (1:2:1 ratio)
Trial: 27089154
Drug: Cognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive enhancement therapy (n = 22)
Trial: 19412196
Drug: biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biologic agents
Trial: 17898955
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (oral intake of vitamin C and E, external application of quban powder)
Trial: 7756226
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid)
Trial: 2156885
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg daily)
Trial: 319816
Drug: Naloxone 0.4
RxNorm normalized name: NALOXONE 0.4MG/0.4ML AUTOINJECTOR,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.4 mg
Trial: 25762759
Drug: Computerized motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized motivational feedback at baseline, 3 months, and 6 months; 12 weeks of cessation counseling and nicotine patches
Trial: 22463614
Drug: sPLA2 threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sPLA2 threshold level ≥ 48 ng/ml
Trial: 15226332
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT)
Trial: 11984215
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (A) 20 mg/day
Trial: 11984215
Drug: Pravastatin (P)
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin (P) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Trial: 11984215
Drug: Simvastatin (S)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (S) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Trial: 11984215
Drug: Pravastatin (P)
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin (P) 20 mg/day + Ciprofibrate (C) 100 mg/day
Trial: 11984215
Drug: Simvastatin (S)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (S) 20 mg/day + Ciprofibrate (C) 100 mg/day
Trial: 2375883
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1500 mg d‐1)
Trial: 497093
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral procainamide preparation 1
Trial: 497093
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral procainamide preparation 2
Trial: 30910320
Drug: β blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blockers (propranolol up to 160 mg twice a day or carvedilol ≤25 mg/day)
Trial: 29135115
Drug: Ipilimumab 3mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab 3mg/kg, administered with short 30-min i.v. infusion every 3 weeks, total of 4 doses
Trial: 26320827
Drug: Modafinil 300mg
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 300mg daily
Trial: 23384300
Drug: Esmolol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.05 mg·kg(‐1) ·min(‐1) after tracheal intubation, 0.3 mg·kg(‐1) ·min(‐1) during CPB, 0.03‐0.05 mg·kg(‐1) ·min(‐1) until the end of surgery)
Trial: 20938439
Drug: Low-fat, high-complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) (1.2 g per day) for 12 weeks
Trial: 17224858
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/day initially, increased to 20 mg/day after 1 week)
Trial: 17224858
Drug: Citalopram +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram + HT (10 mg/day initially, increased to 20 mg/day after 1 week)
Trial: 16595221
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg of desogestrel plus 0.030 mg of ethinyl E2 daily for 12 months
Trial: 16595221
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of cyproterone acetate plus 0.035 mg of ethinyl E2 daily for 12 months
Trial: 12883329
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration for 1 hour
Trial: 11023928
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months
Trial: 9273524
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of intravenous opiate injections and administration of methadone
Trial: 9273524
Drug: Continued injecting
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued injecting drug use (Control group)
Trial: 1642909
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose extradural morphine
Trial: 1642909
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and clonidine
Trial: 26225497
Drug: Sugammadex 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 4 mg/kg
Trial: 30169407
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg and Sugammadex 4 mg/kg
Trial: 23150144
Drug: Risedronate 75
RxNorm normalized name: risedronate 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 75 mg on 2 consecutive days each month (2CDM)
Trial: 9467547
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily
Trial: 19476402
Drug: Risedronate 75
RxNorm normalized name: risedronate 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 75 mg 2CDM
Trial: 21496415
Drug: Leflunomide (LEF)
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide (LEF) at a daily dose of 20 mg
Trial: 21496415
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) at a mean dose of 11.7±2.6 mg/week
Trial: 18510807
Drug: DHA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (800 mg/day)
Trial: 19447020
Drug: Lutein (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (12 mg/day)
Trial: 18510807
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DHA and lutein
Trial: 17130504
Drug: Intensive diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive diabetes treatment during the DCCT
Trial: 17130504
Drug: Conventional diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diabetes treatment during the DCCT
Trial: 17130504
Drug: Prior intensive
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior intensive diabetes treatment
Trial: 11516093
Drug: Lenograstim (glycosylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim (glycosylated recombinant human G‐CSF) 5 microg per kg body weight subcutaneously daily from day 8 after starting chemotherapy.
Trial: 8381931
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (40 mU.m‐2.min‐1)
Trial: 8381931
Drug: Perindopril (converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (converting enzyme inhibitor)
Trial: 28949012
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once daily (OD) PF-04965842
Trial: 28949012
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg OD PF-04965842
Trial: 28949012
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily (TD) PF-04965842
Trial: 23878319
Drug: Vaccine-induced T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced T cells targeting ≥3 gag peptides
Trial: 23878319
Drug: Vaccine-induced T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced T cells
Trial: 20034487
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1 g/day) for 3 months
Trial: 16737416
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg/day for 2 weeks
Trial: 6373156
Drug: Glaucine syrup
RxNorm normalized name: glaucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucine syrup 30 mg 3-times daily for 7 days
Trial: 6373156
Drug: Codeine syrup
RxNorm normalized name: TUSSIREX W/CODEINE SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine syrup 30 mg 3-times daily for 7 days
Trial: 6373156
Drug: Glaucine capsules
RxNorm normalized name: glaucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucine capsules 30 mg 3-times daily for 28 days
Trial: 29753693
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (ALA) 600 mg and sodium ferrous citrate (SFC) 942 mg
Trial: 30931663
Drug: Palacos R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palacos R + G
Trial: 24710342
Drug: Corticosteroids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids treatment within 24 hours after admission
Trial: 19308727
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneously every 6 months
Trial: 12881343
Drug: Partial Tenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial Tenon's capsule resection with adjunctive mitomycin C (MMC)
Trial: 12881343
Drug: Ahmed glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed glaucoma valve implant without PTCR (control group)
Trial: 10966009
Drug: Abciximab treatment
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab treatment during coronary artery bypass grafting
Trial: 1567745
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (S-I)
Trial: 1567745
Drug: Golytely solution
DrugBank: Sodium sulfate (DB09472)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Golytely solution (S-II)
Trial: 1567745
Drug: Digestive irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digestive irrigation with antibiotics
Trial: 2865218
Drug: Bopindolol 1
RxNorm normalized name: bopindolol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol 1 mg (BP1)
Trial: 2865218
Drug: Bopindolol 2
RxNorm normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol 2 mg (BP2)
Trial: 2865218
Drug: Lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.5 mg (LR)
Trial: 2865218
Drug: Butalbital 75
RxNorm normalized name: Butalbital
DrugBank: Butalbital (DB00241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butalbital 75 mg (BT)
Trial: 24885942
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate 3000 mg/day
Trial: 15857067
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of hydroxy-ethyl-methacrylate and glutaraldehyde (HEMA-G)
Trial: 15857067
Drug: Both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both agents (NaF and HEMA-G)
Trial: 15857067
Drug: Teeth requiring
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth requiring repeat dosage
Trial: 11405503
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no thrombolytic therapy)
Trial: 9874451
Drug: EEP (etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, cisplatin 40 mg/m2 on Days 1 and 8)
Trial: 9874451
Drug: FEP (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cisplatin 80 mg/m2 on Day 1)
Trial: 8594118
Drug: Refrigerant topical
RxNorm normalized name: Refrigerant 114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refrigerant topical anesthetic
Trial: 8594118
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical spray
Trial: 19351782
Drug: No-spray control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-spray control
Trial: 38680
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg atropine
Trial: 38680
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg hyoscine
Trial: 38680
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg glycopyrronium
Trial: 23794465
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg·kg(‐1) daily for up to 10 days)
Trial: 18236139
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg) three times per day for 5 days
Trial: 14658947
Drug: Various NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various NSAIDs (including aspirin and sulindac)
Trial: 21055739
Drug: CDB-2914 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (10 mg)
Trial: 10783359
Drug: CDB-2914 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (50 mg)
Trial: 10783359
Drug: CDB-2914 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (100 mg)
Trial: 10783359
Drug: CDB-2914 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB-2914 (all doses)
Trial: 6696210
Drug: Ispaghula suspension
RxNorm normalized name: ISPAGHULA
DrugBank: Plantago ovata seed (DB14585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispaghula suspension (oral challenge)
Trial: 31227014
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg daily for 90 days
Trial: 24378958
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline daily for 4 months
Trial: 22157087
Drug: Mustard preparation
RxNorm normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mustard preparation (20 g, 25 mg total ITC) daily for 4 days
Trial: 20400377
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% w/w capsaicin patch), applied for 60 minutes
Trial: 18568273
Drug: DTaP-IPV//PRP approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 0, 6, and 14 weeks
Trial: 18568273
Drug: DTaP-IPV//PRP approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 6, 10, and 14 weeks